Can You Make Money Off Halozyme Stock Now?
Yahoo! Finance ·
Key points
- Halozyme’s shares fell 21.5% from a late-October high, with most of the decline occurring after its November 6 earnings call, prompting questions about whether royalties will keep growing and if Merck’s litigation can be resolved in Halozyme’s favor.
- Historical analysis notes 21 declines of more than 20% since 2010, with 16 of the 20 declines having a higher stock price a year later, implying potential upside after volatility though with periods of further declines along the way.
- Royalty revenue rose 44% to a record $341 million in Q3, driven by ENHANZE-powered drug conversions and contributions from established partners and newer launches like OCREVUS ZUNOVO and OPDIVO Qvantig.
- On November 6, Halozyme announced accelerated FDA approval of RYBREVANT FASPRO (ENHANZE-based) for head and neck cancer, reinforcing near-term royalty momentum and justifying a raised 2026 growth forecast to 42%–45%.
- The company retains a large portion of revenue as operating profit (about 55.9% over the past year) and generates cash flow of roughly 52.4% of revenue, yet valuation remains below broader indices on operating cash flow, even as earnings multiples sit above market averages.
- Patents remain pivotal: Halozyme has won European rulings but faces validities challenges in the U.S. Merck’s Keytruda Qlex dispute has led to a Dutch ruling in Halozyme’s favor in Europe, while U.S. rulings have been less favorable and appeal proceedings could run through 2028.
- With royalties being the key metric for the investment thesis, the next report (due February 2027) will be critical in confirming whether royalty growth remains intact amid ongoing patent battles and market uptake.
Summary
Halozyme Therapeutics tumbled after its Q3 report on expectations that royalty growth will sustain returns for investors, hinging on ENHANZE-enabled drugs and unresolved patent fights with Merck. Royalty revenue hit a record $341 million in the quarter, helped by established partners and new launches, and management raised the 2026 royalty forecast to 42%–45%. A Dutch court’s ruling favored Halozyme in Europe over Merck’s Keytruda Qlex, while U.S. patent validity challenges remain, setting up a bifurcated path that could shape royalties for years. Historical data shows many past dips recovered within roughly ten months to a year, but resilience will depend on continued patent protection and partner drug uptake. Looking ahead, the next earnings update and ongoing patent appeals will be critical to whether the recent drop proves temporary or signals a longer-term recalibration.
This summary was written with AI. The full story has every detail.